These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18928375)

  • 1. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.
    Kurbanov F; Tanaka Y; Chub E; Maruyama I; Azlarova A; Kamitsukasa H; Ohno T; Bonetto S; Moreau I; Fanning LJ; Legrand-Abravanel F; Izopet J; Naoumov N; Shimada T; Netesov S; Mizokami M
    J Infect Dis; 2008 Nov; 198(10):1448-56. PubMed ID: 18928375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia.
    Zakalashvili M; Zarkua J; Weizenegger M; Bartel J; Raabe M; Zangurashvili L; Kankia N; Jashiashvili N; Lomidze M; Telia T; Kerashvili V; Zhamutashvili M; Abramishvili N; Hedskog C; Chodavarapu K; Brainard DM; McHutchison JG; Mo H; Svarovskaia E; Gish RG; Rtskhiladze I; Metreveli D
    Liver Int; 2018 Mar; 38(3):451-457. PubMed ID: 28782185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 6. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2007; 50(5):361-8. PubMed ID: 17728547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report.
    Morel V; Descamps V; François C; Fournier C; Brochot E; Capron D; Duverlie G; Castelain S
    J Clin Virol; 2010 Apr; 47(4):382-6. PubMed ID: 20153975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

  • 14. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.
    Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C
    Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
    Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
    J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    Susser S; Dietz J; Schlevogt B; Zuckerman E; Barak M; Piazzolla V; Howe A; Hinrichsen H; Passmann S; Daniel R; Cornberg M; Mangia A; Zeuzem S; Sarrazin C
    J Hepatol; 2017 Oct; 67(4):680-686. PubMed ID: 28619439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.
    Inoue K; Umehara T; Ruegg UT; Yasui F; Watanabe T; Yasuda H; Dumont JM; Scalfaro P; Yoshiba M; Kohara M
    Hepatology; 2007 Apr; 45(4):921-8. PubMed ID: 17393519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
    Pradat P; Maynard M; Buti M; Berthillon P; Picchio G; Tillmann HL; Wiegand J; Voirin N; Manns MP; Esteban JI; Martinot M; Marcellin P; Trepo C
    J Med Virol; 2004 Jul; 73(3):392-6. PubMed ID: 15170634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.